University Hospital of Wales, Cardiff, UK
Cardiff University, Cardiff, UK.
BMJ Open. 2024 Sep 10;14(9):e089722. doi: 10.1136/bmjopen-2024-089722.
Very preterm babies are at risk of poor neurodevelopmental outcomes and death. Intraventricular haemorrhage (IVH) after birth is the most prevalent cause of this. Birth by caesarean section may protect against IVH in very preterm babies, but the evidence is limited. The aim is to identify and obtain the quantitative evidence needed to inform a future definitive clinical trial to determine the optimal mode of delivery in preterm birth.
We will use three broad workstreams (WS) to answer complementary questions. WSs 1 and 2 involve the analysis of routinely recorded national clinical data held in an established research database. In WS1 (October 2023-March 2024), we will use conventional methods to identify what is needed to undertake a trial: the population of interest, areas of equipoise and a plausible range of effect sizes. In WS2 (April 2024-October 2024), using an emulated target trial framework, we will attempt to make inferences about the treatment effect from such a future trial and will identify potential challenges in recruitment and estimate likely 'intention-to-treat' versus 'per-protocol' profiles; these analyses will also be useful for power calculations for future possible trials. In WS3 (October 2024-March 2025), we will convene a consensus meeting with key stakeholders, supported by a clinical trials unit, to develop a multicentre clinical trial to identify the optimal mode of birth for preterm deliveries.
In this study, we will use deidentified data held in the National Neonatal Research Database (NNRD), an established national population database; parents can opt out of their baby's data being held in the NNRD. HRA/Health and Care Research Wales and National Health Service (NHS) study-specific Research Ethics Committee approval (London-Queen Square Research Ethics Committee) (Ref: 23/LO/0826) ethical approval has been obtained. Key outputs of the PRECIOUS (PREterm Caesarean/vaginal birth and IVH/OUutcomeS) study include the identification of the data, and accordingly of the multidisciplinary team required, to develop, gain funding and complete, a clinical trial to definitively identify the optimal mode of delivery for preterm infants and their mothers.
早产儿存在神经发育不良和死亡的风险。出生后的脑室出血(IVH)是最常见的原因。剖宫产可能会降低早产儿 IVH 的风险,但证据有限。目的是确定并获得定量证据,为未来的临床试验提供信息,以确定早产的最佳分娩方式。
我们将使用三个广泛的工作流程(WS)来回答互补的问题。WS1 和 WS2 涉及对已建立的研究数据库中常规记录的国家临床数据的分析。在 WS1(2023 年 10 月至 2024 年 3 月)中,我们将使用常规方法确定开展试验所需的条件:感兴趣的人群、平衡点领域和合理的效果大小范围。在 WS2(2024 年 4 月至 2024 年 10 月)中,我们将使用模拟目标试验框架,尝试从未来的试验中推断治疗效果,并确定招募方面的潜在挑战,并估计可能的“意向治疗”与“按方案”的情况;这些分析也将有助于为未来可能的试验进行功效计算。在 WS3(2024 年 10 月至 2025 年 3 月)中,我们将在临床试验单位的支持下,与主要利益相关者召开共识会议,制定一项多中心临床试验,以确定早产分娩的最佳分娩方式。
在这项研究中,我们将使用国家新生儿研究数据库(NNRD)中保存的匿名数据,这是一个已建立的全国人口数据库;父母可以选择不将其婴儿的数据保存在 NNRD 中。HRA/威尔士健康与护理研究和国民保健制度(NHS)特定研究伦理委员会(伦敦-皇后广场伦理委员会)(参考号:23/LO/0826)已获得批准。PRECIOUS(PREterm Caesarean/vaginal birth and IVH/OUutcomeS)研究的主要成果包括确定数据,以及确定开发、获得资金和完成临床试验所需的多学科团队,以明确确定早产儿及其母亲的最佳分娩方式。